deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03494179

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Conditions Mantle Cell Lymphoma
Interventions ICP-022
Updated 14 times since 2018 Last updated: Jun 2, 2023 Started: Apr 2, 2018 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Mantle Cell Lymphoma, this trial is ongoing. The trial is conducted by Beijing InnoCare Pharma Tech Co., Ltd. and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2022 · 15 months · monthly snapshot~Sep 2022 – ~Jul 2023 · 10 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Unknown PHASE1/PHASE2

    Status: Active Not Recruiting → Unknown

  3. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Jul 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Sep 2022 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jun 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Apr 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jul 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jun 2018 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing InnoCare Pharma Tech Co., Ltd.
Data source: Beijing InnoCare Pharma Tech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Chengdu, China , Dalian, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Hefei, China , Jinan, China , Nanjing, China and 9 more locations